Specific oncological contribution of cathepsin D and pS2 in human breast cancer: Their relationship with TNM status, estradiol receptors, epidermal growth factor receptor and neu amplification

Clinica Chimica Acta

Volumn 247, Issue 1-2, 1996, Pages 89-103

  Bolufer Gilabert, P ^a   Torregrosa, M D ^b   Gomez, L ^a   Munarriz, B ^a   Lopez J A ^a   Asins, E ^a   Espinoza, S ^a   Vera, F ^a   Vazquez, C ^b   Guillem, V ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

breast cancer; cathepsin D; epidermal growth factor receptor; estradiol receptors; neu emplification; pS2; TNM status

Indexed keywords

CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; FEMALE; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 18844470861     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/0009-8981(95)06247-5     Document Type: Article

References (27)

1. Rocheford H. Cathepsin D in breast cancer. Breast Cancer Res Treat 1990;16:3-13.
2. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P. Cloning of cDNA sequences of hormone regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 1982;10:7895-7903.
3. Brown AMC, Jeltsch JM, Roberts M, Chambon P. Activation of pS2 gene transcription in primary response to estrogen in human breast cancer cell line MCF-7. Proc Natl Acad Sci (Wash) 1984;81:6377-6348.
4. Gazin JL, Gosselin P, Boniface B, Boniface M, Demaille A. Expression of pS2 and cathepsin D in breast cancer. Int J Oncol 1993;2:1081-1084.
5. Marsigliane S, Biscozzo L, Correale M et al. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors. Br J Cancer 1994;69:550-554.
6. Correale M, Paradiso A, Abbate I et al. Cytosolic levels of estrogen-regulated pS2 protein in breast cancer: correlation with tumor proliferative activity. Tumor Biol 1993;14:30-37.
7. Rio MC, Bellocq JP, Gairard B et al. Specific expression of pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci USA 1987;84:9243-9247.
8. Foekens JA, Rio MCh, Seguin P et al. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 1990;50:3832-3837.
9. Koerner FC, Goldberg DE, Edgerton SM, Schwartz LH. pS2 protein and steroid hormone receptors in invasive breast carcinomas. Int J Cancer 1992;52:183-188.
10. Sacks NPM, Smith K, Norman AP, Greenall M, Le Jeune S, Harris AL. Cathepsin D levels in primary breast cancers: relationship with epidermal growth factor receptor, oestrogen receptor and axillary nodal status. Eur J Cancer 1993;29A:426-428.
11. Foekens JA, van Putten WLJ, Portengen H et al. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. J Clin Oncol 1993;11:899-908.
12. Bloom HJG, Richardson WW. Histologic grading and prognosis in breast cancer. Br J Cancer 1957;11:359-377.
13. Benraad TJ, Geurts-Moespot A, Sala M, Piffanelli A, Ross A, Foekens JA, EORTC Receptor Study Group. Quality Control of Cathepsin D measurement by the EORTC Receptor Study Group. Eur J Cancer 1992;28:72-75.
14. Bradford MM. A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Ann Biochem 1976;72:248-254.
15. Bolufer P, Molina R, Ruiz A, Hernandez M, Vazquez C, Lluch A. Estradiol receptor in combination with neu oncogene amplification might define new subtypes of breast cancer. Clin Chim Acta 1994;229:107-122.
16. Maniatis T, Fritsch E, Sambrook J. Molecular cloning. A laboratory manual. New York: Cold Spring Harbor Laboratory, 1982.
17. DNA Labelling and detection nonradioactive. Applications manual. West Germany: Boehringer Mannheim GmbH Biochemica, 1989.
18. Bolufer P, Miralles F, Rodriguez A et al. Epidermal growth factor receptor in human breast cancer: correlation with cytosolic and nuclear ER receptors and with biological and histological tumor characteristics. Eur J Cancer 1990;26:283-290.
19. Leake RE, Laing L, Smith DC. A role for nuclear estrogen receptors in prediction of therapy regime for breast cancer patients. In: King RJB, ed. Steroid receptor assays in human breast tumors: methodological and clinical aspects. Cardiff: Alpha Omega Press, 1979;75-86.
20. Armitage P. Statistical methods in medical research. Oxford, London: Blackwell Scientific Publications, 1977.
21. Pujol P, Maudelonde T, Daures JP et al. A prospective study of the prognostic value of cathepsin D levels in breast cancer. Cancer 1993;1:2006-2012.
22. Speiser P, Stolzlechner J, Haider K et al. pS2 protein status fails to be and independent prognostic factor in an average breast cancer population. Anti Res 1994;14:2121-2130.
23. Tetu B, Brisson J, Côté Ch, Brisson S, Potvin D, Roberge N. Prognostic significance of cathepsin D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer 1993;55:429-435.
24. Fernö M, Baldetorp B, Borg A et al. Cathepsin D, both prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. Eur J Cancer 1994;30A:2042-2048.
25. Brouillet JP, Theillet Ch, Maudelonde T et al. Cathepsin D assay in primary breast cancer and lymph nodes: Relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness. Eur J Cancer 1990;26:437-441.
26. Ravdin PM, Tandon AK, Allred DG et al. Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol 1994;12:467-474.
27. Spyratos F, Brouillet JP, Defrenne A et al. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet 1989;2:1115-1118.